Loss of Heterozygosity in the Tumor DNA of De Novo Diagnosed Patients Is Associated with Poor Outcome for B-ALL but Not for T-ALL

Natalya Risinskaya 1, Yana Kozhevnikova 2, Olga Gavrilina 1, Julia Chabaeva 1, Ekaterina Kotova 1, Anna Yushkova 1, Galina Isinova 1, Ksenija Zarubina 1, Tatiana Obukhova 1, Sergey Kulikov 1, Hunan Julhakyan 1, Andrey Sudarikov 1,* and Elena Parovichnikova 1

Abstract: Despite the introduction of new technologies in molecular diagnostics, one should not underestimate the traditional routine methods for studying tumor DNA. Here we present the evidence that short tandem repeat (STR) profiling of tumor DNA relative to DNA from healthy cells might identify chromosomal aberrations affecting therapy outcome. Tumor STR profiles of 87 adult patients with de novo Ph-negative ALL (40 B-ALL, 43 T-ALL, 4 mixed phenotype acute leukemia (MPAL)) treated according to the “RALL-2016” regimen were analyzed. DNA of tumor cells was isolated from patient bone marrow samples taken at diagnosis. Control DNA samples were taken from the buccal swab or the blood of patients in complete remission. Overall survival (OS) analysis was used to assess the independent impact of the LOH as a risk factor. Of the 87 patients, 21 were found with LOH in various STR loci (24%). For B-ALL patients, LOH (except 12p LOH) was an independent risk factor (OS hazard ratio 3.89, log-rank p-value 0.0395). In contrast, for T-ALL patients, the OS hazard ratio was 0.59 (log-rank p-value 0.62). LOH in particular STR loci measured at the onset of the disease could be used as a prognostic factor for poor outcome in B-ALL, but not in T-ALL.

Keywords: short tandem repeat (STR); acute lymphoblastic leukemia; loss of heterozygosity (LOH); uniparental disomy (UPD); chromosomal microarray (CMA)

1. Introduction

Acute lymphoblastic leukemia is a malignant neoplasm characterized by the proliferation of lymphoid cell precursors leading to infiltration of the bone marrow by lymphoblasts. Risk stratification is based on demographic and clinical factors (such as age, ethnicity, gender, blood count at diagnosis, cell lineage, CNS involvement), genetic features of tumor cells, and response to treatment [1]. Conventional cytogenetic analysis complemented with fluorescence in situ hybridization (FISH) is used to detect chromosomal abnormalities and determine risk groups. However, due to inadequate specimens or lack of mitotic cells, these methods are often ineffective. Among ALL patients with a cytogenetic result, 15% to 50% have a normal karyotype [2,3]. Moreover, the above methods are unable to detect copy number neutral loss of heterozygosity (LOH), which can result in deregulation of cell division and apoptosis through the deletion of tumor suppressor genes [4]. Copy number neutral LOH in malignant tumors is a result of somatic uniparental disomy (UPD). UPD occurs due to mitotic homologous recombination events, as attempts to correct the deletion of chromosomal material by using the remaining alleles as a template, or mitotic
Genes 2022, 13, 398

2 of 10

errors including chromosomal missegregation [5]. Thus, LOH analysis can detect areas of allelic loss not revealed by standard cytogenetic analysis. Moreover, LOH analysis is an effective tool for identifying “masked hypodiploidy”, when patients do not have a karyotypically visible clone with ≤43 chromosomes and, instead, their abnormal karyotypes contain 50–78 or more chromosomes from doubling of previously hypodiploid cells [6]. Genetic instability of tumor cells can lead to a change in the profile of short tandem repeats (STRs, or microsatellites) which are hypervariable and highly mutable simple repetitive DNA sequences [7]. Several studies regarding LOH analysis of childhood ALL using microsatellite markers have been published [8–12]. In these studies, the highest rates of allelic losses were observed in chromosomes 9p and 12p, and a lower frequency of LOH was observed at 5p, 6q, 10p, and 20q. Takeuchi et al. also evaluated the correlation between LOH analysis findings and clinical characteristics and showed that those with 6q LOH had lower WBC counts, patients with 9p LOH more frequently had CNS involvement, individuals with 11q LOH had a good response to induction chemotherapy, and those with 12p LOH had a higher event-free survival rate [8]. There were few genome-wide LOH studies using microsatellite markers of adult ALL [13]; several studies of adult ALL patients were dedicated to LOH in individual chromosomes [14–17]. In all studies, the frequency of LOH detected by microsatellite analysis was much higher than the reported frequency of cytogenetic aberrations on corresponding chromosomal arms. Our objective was to identify LOH in the blast cells of the patients with B- and T-ALL at diagnosis and to analyze therapy outcomes according to LOH status.

2. Materials and Methods

Samples from 87 patients with newly diagnosed nontreated Ph-negative ALL (40 B-ALL, 43 T-ALL, 4 MPAL) were included in the study. The median age was 33 (18–55 years), 52 (60%) were men, and 35 (40%) were women. All patients were treated according to the “RALL-2016” regimen (ClinicalTrials.gov identifier: NCT03462095) at the National Research Center for Hematology (Moscow, Russia). Cryopreserved pretreatment bone marrow samples and the results of the standard cytogenetic analysis were available for these patients.

Tumor DNA was isolated from patients’ bone marrow samples taken at diagnosis. Control DNA was isolated from the buccal swab or blood of patients in complete remission. STR profiles for each pair of samples (tumor/control) were assessed by PCR with primers to 19 STR loci and amelogenin locus available in CorDis Plus multiplex kit (Gordiz Ltd., Moscow, Russia). We used the following markers: D1S1656 (locus 1q42), D2S441 (locus 2p14), D3S1358 (locus 3p21.31), D5S818 (locus 5q23.2), D7S820 (locus 7q21.11), D8S1179 (locus 8q24.13), D10S1248 (locus 10q26.3), D12S391 (locus 12p13.2), D13S317 (locus 13q31.1), D16S539 (locus 16q24.1), D18S51 (locus 18q21.33), D21S11 (locus 21q21.1), D22S1045 (locus 22q12.3), CSF1PO (locus 5q33.1), FGA (locus 4q31.3), SE33 (locus 6q14), TH01 (locus 11p15.5), TPOX (locus 2p25.3), VWA (locus 12p13.31), amelogenin X (locus Xp22.1–22.3), and amelogenin Y (locus Yp11.2). For fragment analysis of PCR products, genetic analyzer ABI 3130 (Thermo Fisher Scientific, USA) was used. STR profiles were then analyzed using GeneMapper Software. LOH status was not detected for patients with blast percentage in bone marrow less than 50% (four B-ALL patients and one T-ALL patient).

For all patients with LOH in STR loci, tumor DNA lesions were verified by chromosomal microarray (CMA CytoScan HD) (Figure 1).

Statistical analysis: We used standard methods of descriptive statistics, frequency, and event analysis. To test hypotheses about the differences in the distributions of categorical features in the comparison groups, the analysis of contingency tables was used. The χ2 criterion was used to assess the significance; odds ratio (OR) with the corresponding 95% confidence interval (CI) was used as a measure of connection. To test the hypotheses about the presence of differences in the distributions of numerical indicators in the comparison groups, the nonparametric Mann–Whitney rank test was used. In event analysis, the Kaplan–Meier estimates were used to assess the distributions, and the log-rank test was
used to assess the statistical significance of differences in the groups. Statistical analysis was performed using the procedures of the SAS 9.4 package. Censoring was done at the date of the last contact for surviving subjects. EFS was defined as the interval from complete remission to relapse or death or last contact. OS was defined as the interval from randomization to death or last contact.

Figure 1. LOH patterns in STR profile of B-ALL patient 45 (a,b) molecular karyoview of CMA. The karyoview presents a diagram of all copy number variations (red bar for loss; blue bar for gain) and copy neutral LOH (purple bar). (LOH at 1q42, 10q26.3, 6q14, and 18q21.33 and disbalance at amelogenin X/amelogenin Y were verified by CMA as gains in areas including aberrant STR loci).

3. Results

The main characteristics of patients by phenotype are included in Table 1. Among 87 patients, 37 had normal cytogenetic karyotype, 45 had abnormal cytogenetic karyotype, and in 5 patients it was not possible to determine the karyotype by cytogenetic analysis.
due to the absence of mitosis in the test material. After comparing the STR profiles of the DNA of tumor cells and healthy cells for each patient, we found a loss or decrease in the signal from one of a pair of alleles at heterozygous STR loci in 21 patients out of 87 (24.1%). Of these 21 patients, 7 had a normal tumor karyotype and 14 had an abnormal one. In 8 out of 14 patients with an abnormal karyotype, LOH was also found on chromosomes that were not aberrant according to cytogenetic analysis data. Thus, analysis of STR profiles revealed additional abnormalities in seven patients with normal karyotype and eight with abnormal karyotype, which is 17.2% of the cohort.

Table 1. The main characteristics of the patients.

|                | B-ALL (n = 40) | T-ALL (n = 43) | MPAL (n = 4) |
|----------------|---------------|---------------|--------------|
| Male:Female    | 20:20         | 28:15         | 4:0          |
| Age, median    | 36 (19–61) years | 33 (20–50) years | 32 (27–36) years |
| Leukocytes, 10^9/L | 9.25 (1.39–593.48) | 44.9 (1.09–833.94) | 3.82 (1.79–5.69) |
| LDH            | 964 (221–20,062) | 1447 (120–20,064) | 308 (154–1052.6) |
| Blast cells in peripheral blood, % | 56 (0–98) | 67.5 (0–96) | 1 (0–71) |
| Blast cells in the bone marrow, % | 80 (0–96.8) | 86.6 (0–100) | 36.8 (31.2–74.8) |
| Immunophenotype, EGIL, WHO | B-I 7 (17.5%) ETP (T-I) 4 (9.3%) T/myelo 2 (50%) | B-II 31 (77.5%) ETP (T-II) 2 (4.7%) B/myelo 1 (25%) |
| B-III 1 (2.5%) T-II 11 (25%) T/B 1 (25%) |
| B-IV 1 (2.5%) T-III 23 (54%) T-IV 3 (7%) |
| Standard cytogenetics | + mitosis 37 (92.5%) | 41 (95.3%) | 4 (100%) |
| – mitosis 3 (7.5%) | 2 (4.7%) |
| Karyotype      | Normal 16 (40%) | 17 (39.5%) | 4 (100%) |
| Abnormal:      | 21 (52.5%) | 24 (55.8%) | |
| Complex (>3 chromosomal aberrations) | 6 | 5 | |
| Hyperploid     | 4 | 1 | |
| Other          | 11 | 17 | |
| CNS leukemia   | 6 (15%) | 9 (20.9%) | 0 (0%) |
| Extramedullary disease | 11 (27.5%) | 27 (62.8%) | 3 (75%) |
| CR             | After 2nd induction (+70 day) | 35 | 40 | 2 (50%) |
| Refractory disease | 4 | 3 | 2 (50%) |
| Death in CR    | 1 | | |

* B-ALL, B-cell lymphoblastic leukemia; T-ALL, T-cell lymphoblastic leukemia; MPAL, mixed phenotype acute leukemia; LDH, lactate dehydrogenase; EGIL, European Group on Immunological Classification of Leukemia; WHO, World Health Organization; ETP, early T-cell precursor; CNS, central nervous system; CR, complete remission.

The most frequent LOH at 12p was detected in eight patients (9.2% of patients). Other frequent loci with LOH included 6q (five patients, 5.7%), 1q (four patients, 4.6%), and 4q (four patients, 4.6%). It is noteworthy that in T-ALL the loss of heterozygosity covers a smaller set of STR loci than in B-ALL. The full distribution of LOH by loci is presented in Supplementary Materials Tables S1–S3.

According to OS analysis, LOH 12p seems to be a marker of a favorable prognosis (Figure 2). Patients with the 12p LOH are excluded from the risk group because 12p LOH is not associated with worse outcome according to our data and [8,18].

We have checked the distributions of all major risk factors such as age, gender, leukocyte count at diagnosis, LDH level, blast cell percentage in the bone marrow and peripheral blood, immunophenotype, standard cytogenetic karyotype, CNS leukemia, extramedullary disease, and complete remission/refractory after second induction (+70 days) in groups B-ALL and T-ALL in relation to LOH status. We have found no significant differences between the analyzed groups (Tables 2 and 3), with one exception: in T-ALL the percentage of blast cells in bone marrow was significantly higher in the LOH-positive group (p = 0.02).
smaller set of STR loci than in B-ALL. The full distribution of LOH by loci is presented in Supplementary Materials Tables S1–S3.

According to OS analysis, LOH 12p seems to be a marker of a favorable prognosis (Figure 2). Patients with the 12p LOH are excluded from the risk group because 12p LOH is not associated with worse outcome according to our data and [8,18].

Figure 2. Kaplan–Meier survival curve for OS estimates according to the LOH status in tumor STR profile (LOH (except LOH 12p), red line; LOH 12p, green line; no LOH, blue line). Four patients with LOH 12p and additional LOH in several loci and five patients with unidentified LOH status were excluded from analysis.

We have checked the distributions of all major risk factors such as age, gender, leukocyte count at diagnosis, LDH level, blast cell percentage in the bone marrow and peripheral blood, immunophenotype, standard cytogenetic karyotype, CNS leukemia, extramedullary disease, and complete remission/refractory after second induction (+70 days) in groups B-ALL and T-ALL in relation to LOH status. We have found no significant differences between the analyzed groups (Tables 2 and 3), with one exception: in T-ALL the percentage of blast cells in bone marrow was significantly higher in the LOH-positive group (p = 0.02).

| LOH-Positive * (n = 10) | LOH-Negative (n = 26) | p χ² |
|-------------------------|-----------------------|------|
| Male:Female             | 6:4                   | 1:15 |
| Age, median             | 34.5 (19–61) years    | 36 (21–53) years |
| Leukocytes, 10⁹/L       | 10.76 (1.40–34.39)    | 5.66 (1.09–593.48) |
| LDH, U/L                | 1439 (221.00–20,062.00) | 615.50 (293–7348.8) |
| Blast cells in peripheral blood, % | 52.5 (1–89) | 15 (0–98) |
| Blast cells in the bone marrow, % | 84.20 (70–95.8) | 79 (0–200) |
| Immunophenotype, EGIL, WHO | B-II 9 (90%) | B-I 7 (27%) |
| Standard cytogenetics   |                       |      |
| + mitosis               | 9 (90%)               | 24 (92.3%) |
| − mitosis               | 1 (10%)               | 2 (7.7%) |
| Karyotype               |                       |      |
| Normal                  | 2 (20%)               | 10 (38.5%) |
| Abnormal:               | 7 (70%)               | 14 (53.8%) |
| Complex (>3 chromosomal aberrations) | 5 (3 deaths) | 1 |
| Hyperplod               | 1                     | 3 live |
| Other                   | 1                     | 10    |
| CNS leukemia             | 2                     | 3     |
| Extramedullary disease  | 2                     | 8     |
| CR                      |                       |      |
| After 2nd induction (+70 day) | 10                  | 23    |
| Refractory disease      | 0                     | 3     |
| 2-year OS               | 50%                   | 83%   |
| 2-year RFS              | 50%                   | 85%   |

* For four B-ALL patients, LOH status was not detectable due to blast percentage in bone marrow being less than 50%.

Therefore, we conclude that the influence of LOH on clinical output is not due to its correlation with some known risk factors. For B-ALL patients, LOH (excepting 12p LOH) was an independent risk factor (OS hazard ratio 3.89, log-rank p-value 0.0395) (Figure 3a). For T-ALL patients, OS hazard ratio was 0.59 (log-rank p-value 0.62) (Figure 3b).
Table 3. The main characteristics of T-ALL patients according to the LOH status. *p*-value from $\chi^2$ was used to estimate significance for the tables of $2 \times 2$.

| LOH-Positive * ($n = 9$) | LOH-Negative * ($n = 33$) | $p \chi^2$ |
|-------------------------|---------------------------|------------|
| Male:Female             | 6:3                       | 21:12      |
| Age, median             | 31.5 (20–37) years        | 33 (20–50) years |
| Leukocytes, $10^9$/L median | 80.35 (9–833.94)          | 23 (2.06–333.21) |
| LDH, U/L                | 1738.5 (415–20,064.3)     | 1299 (120–7633.2) |
| Blast cells in peripheral blood, % median | 75.5 (6–96)           | 60.0 (0–92) |
| Blast cells in the bone marrow, % median | 93.4 (66–98)         | 82.4 (0–100) |
| **Immunophenotype, EGIL, WHO** | T-II 1 (11%)T-III 8 (89%) | T-II 9 (27.3%) |
| | | T-III 15 (45.5%) |
| | | T-IV 3 (9.1%) |
| **Standard cytogenetics** | | |
| + mitosis | 9 (100%) | 31 (94%) |
| – mitosis | 0 | 2 (6%) |
| Karyotype | | |
| Normal | 3 (33.3%) | 12 (36.4%) |
| Abnormal: | 6 (66.7%) | 19 (57.6%) |
| Complex (>3 chromosomal aberrations) | - | 5 |
| Hyperploid | - | 1 |
| Other | 6 | 13 |
| CNS leukemia | 2 (22.2%) | 6 (18%) |
| Extramedullary disease | 5 (55.6%) | 24 (72.7%) |
| CR | | |
| After 2nd induction | 8 | 31 |
| Refractory disease | 1 | 2 |
| 2-year OS | 88% | 73% |
| 2-year RFS | 100% | 69% |

* For one T-ALL patient, LOH status was not detectable due to blast percentage in bone marrow being less than 50%.

Therefore, we conclude that the influence of LOH on clinical output is not due to its correlation with some known risk factors. For B-ALL patients, LOH (excepting 12p LOH) was an independent risk factor (OS hazard ratio 3.89, log-rank $p$-value 0.0395) (Figure 3a). For T-ALL patients, OS hazard ratio was 0.59 (log-rank $p$-value 0.62) (Figure 3b).

Figure 3. Kaplan–Meier survival curve for OS estimates according to the LOH status in tumor STR profile for B-ALL (a) and T-ALL (b) patients. Patients 3, 4, 43, and 65 were excluded from the LOH group due to 12p LOH.

The main findings concerning karyotypes and microarray data of the patients with aberrant tumor STR profiles are summarized in Table 4.
Table 4. The karyotypes and microarray data of the patients with aberrant STR profiles in tumor DNA.

| # | All Phenotype | Aberrant STR Loci | Karyotype | Microarray |
|---|---------------|-------------------|-----------|------------|
| 29 | B-II 1q42, 13q31.1, 6q14 | 45,XX,del(6)(q12),i(7)(q10),add(13)(p?q?)<sup>[10]</sup>/46,XX,i(7)(q10),del(13)(q22),add(19)(p?q?)<sup>[11]</sup>/46,XX,add(3)(q26),del(6)(q12),<sup>(7)(q10)</sup>add(19)(p?q?)<sup>[11]</sup>/46,XX<sup>[8]</sup> | Gain 1q, loss 6q, loss 7p, gain 7q, loss 13q |
| 32 | B-II 3p21.3 | 51,XX,del(1)(p13.1),+del(4)(q28),+5,+8,der(9),<sup>del(13)(q14q22),+13,der(15),del(17)(q23),+21[15]/46,XX</sup> </p> | Gain 1q, LOH 3 chr, gain 5 chr, 7 chr, 8 chr, loss 13q, gain 21q |
| 39 | B-II 7q21, 4q31, 16q24.1, 5q33, 5q23.2 | 46,XY<sup>[27]</sup>/45,XY,-Y<sup>[1]</sup>,46,XY<sup>[11]</sup>/46,XY,add(1)(q44)<sup>[11]</sup> | Gain 1 chr, 2 chr, loss 5q, gain 6 chr, loss 9chr, gain 10 chr, 12 chr, 14q, loss 15q, 16q, gain 18chr, 19 chr, 21q, 22q |
| 45 | B-II Imbalance X/Y, 1q42, 10q26, 6q14, 4q31,18q21.33 | n/a | Gain 1q, 4 chr, 6 chr, LOH 9 chr, gain 10 chr, 14q, loss 16q, gain 17 chr, 18 chr, 21 chr, X chr |
| 63 | B-II 5q23.2 | 46,XX<sup>[20]</sup> | n/a |
| 65 | B-II 12p13.2 | 46,XY,-7,add(12)(p?),add(12)(p?),+7,+mar<sup>[cp8]</sup>/46,XY<sup>[22]</sup> | Loss 7q, 12p, gain 17p |
| 89 | B-IV 1q42, 12p13.2, 16q24.1, 22q12.3 | 49,XY,+1,der(1)(p10),der(3),<sup>del(6)(p23),der(8)(p9)(p23),+12</sup><sup>,t(14;18)(q32;q21),+16,der(17)[20]</sup> | Gain 1q, LOH 2p, 2q, 3p, 3q, gain 4p, LOH 5p, 5q, gain 8q, 10p, LOH 12p,16p, 16q, gain 18q |
| 71 | B-II Imbalance X/Y, 8q24.13, 10q26.3,18q21.33, 4q31.3, 6q14 | 57,XY,+X,+4,+6,+8,+10,+14,+17,+18,+21x2,+mar<sup>[14]</sup> | Gain 4p, 4q, 6p, 6q, 8p, 8q,10p, 10q, 14q,16q, 17p, 17q, 18p, 18q,20q, Xp |
| 82 | B-II 6q14 | 46,XX<sup>,del(6)(q22),-7,add(19)(p?q?) or der(19)(p19)(q23p13),+mar<sup>[cp7]</sup>/46,XX<sup>[3]</sup> | Gain 1q, loss 6q, 9p, gain 9q |
| 91 | B-II 1q42, 5q23.2 | 46,XY,der(7)(t(7)(q10p21)[15]/46,XY,der(7)(t(7)(q10p21)[21]/46,XY<sup>[14]</sup>| Gain 1q, LOH 5q23 |
| 2 | T-III 10q26.3 | 46, XY<sup>[30]</sup> | LOH 9p, LOH 10q |
| 3 | T-II 12p13.2, 12p13.3 | 46, XY | Gain 5p, 6q, loss 9p, 12p, gain 17q, 18p,18q, 19p |
| 4 | T-III 12p13.2 | 47,Y?X(19)(p21;?p13q13),der(18)+der(19)i(19)(q23p13),+mar<sup>[cp7]</sup>/46,XY<sup>[3]</sup> | Loss 12p, 18p, 18q, gain 19p, Xp |
| 33 | T-III 12p13.2, 12p13.31, 4q31.3 | 46,XY<sup>,t(7)(9)(p14p23),der(14)(26)/46,XY<sup>7</sup>[7] | LOH 4q, loss 7p, LOH 9p, gain 9q, LOH 12p, loss 14q |
| 43 | T-III 12p13.2 | No data | Loss 9p, gain 9q, loss 12p,12q, 13q |
| 64 | T-III 21q21.1, EMAST 4q31.3 | 46,XX<sup>[28]</sup>/47,XX,+mar<sup>[11]</sup>/47,XX,+9,i(9)(q10)[1] | Gain 21q |
| 66 | T-III 10q26.3 | 46,XY<sup>[19]</sup>/46,XY,del(7)(p11)[1] | n/a |
| 85 | T-III 11p15.5 | 46,XY<sup>[20]</sup> | n/a |
| 88 | T-III 6q14 | t(2;14)(q36q22)<sup>[15]</sup>/46,XX<sup>[10]</sup> | Loss 3p, gain 3q, 5p, loss 6q |
| 7 | MPAL 5q33.1 | 46,XY,add(1)(q44), ders (17 i ?(17)(q10)[1]/46,XY<sup>[24]</sup> | Gain 3q, loss 5q, loss 12q, LOH 17p |
| 99 | MPAL 2p14, 7q21, 13q31, 16q24, 18q21, 21q21, 2p25, 12p13.31 | n/a | LOH 8q, loss/LOH 2p, LOH 7q21.3q22.1 and many mosaic LOH less than 5 × 10<sup>6</sup> bp |

## patient number.

4. Discussion

It is known from classical studies that karyotyping of bone marrow before treatment is an important part of adult acute lymphocytic leukemia diagnosis and provides important prognostic information [19]. Therefore, standard cytogenetic analysis has been routinely performed in all patients at the onset of the disease. With the development of molecular technologies, new methods for assessing the tumor genome have been proposed, many of which are used in scientific works, but have not been introduced into routine practice.
yet. With the development of microarray analysis, it has become possible to screen the genome for copy number alterations (CNAs) and regions of copy neutral loss of heterozygosity (cnLOH) that are not detectable by G-banding or fluorescence in situ hybridization (FISH) [20,21].

In this study, we aimed to develop a robust and simple molecular method to identify patients with additional chromosomal lesions otherwise detectable by CMA only. Therefore, we chose STR-PCR to compare tumor and “healthy” genomic DNA. Due to the high polymorphism of STR loci in the population, most of them are present in humans in a heterozygous form; therefore, a wide STR panel could reveal the loss of heterozygosity, which later might be verified by CMA.

We performed LOH analysis of chromosome arms 1q, 2p, 3p, 4q, 5q, 6q, 7q, 8q, 10q, 11p, 12p, 13q, 16q, 18q, 21q, and 22q using STR markers. LOH was detected in 24.1% of ALL patients, with the highest frequency of LOH in the 12p chromosome arm. As compared with standard cytogenetic analysis, we were able to detect additional abnormalities in 15 (17.2%) out of 87 patients using STR profile analysis. Thus, cytogenetic analysis is insufficient for the detection of LOH in ALL patients.

We observed a statistically significant association of poor outcome with the LOH in STR loci (excluding 12p LOH) measured at the onset of B-ALL, but not of T-ALL. For B-ALL patients, the most abundant STR loci with LOH observed were D1S1656 (1q42, four patients), SE33 (6q14, four patients), and FGA (4q31.3, three patients). No significant associations of LOH in particular loci with clinical events were found. Patients 29, 32, 63, and 89 did not achieve remission and died; patients 39, 82, and 91 are still on therapy; and patients 45 and 71 are in remission. One can speculate that gains might be less harmful (patients 45 and 71, Table 4) since no loss of genetic material occurred. One limitation of our study is the fact that our STR panel did not contain markers for several chromosome arms, including 9p. For one T-ALL patient with normal karyotype and the only one LOH in 10q26.3 (patient 2), additional cnLOH at 9p (24.3–13.3) was revealed by chromosomal microarray. CMA also showed the microdeletion at 9p21.3 (2165682_22304230) affecting the region of cnLOH (Table S4). As a result of these two chromosomal aberrations leading to a homozygous form of deletion, a cluster of MTAP, CDKN2A-AS1, CDKN2A, CDKN2B-AS1, and CDKN2B genes containing three onc suppressor genes involved in the regulation of antiproliferative and proapoptotic activities of Rb1 and p53 was completely deleted from the tumor cell genome. The affected patient had the highest level of leukocytes (834 × 109/L) at diagnosis; he died from refractory disease. Abnormalities affecting the 9p chromosome are frequent in ALL patients and associated with a negative impact on survival and increased risk of treatment failure [22–24]. Therefore, the STR panel used in our study needs to be further expanded with markers located in the most frequent and prognostically important loci.

We also tried to assess the LOH 12p as a separate risk factor. LOH 12p seems to be a marker of a favorable prognosis, but the group of patients with LOH 12p without any other LOH variants is too small (four patients only) to assess statistical significance.

The predictive value of copy number variations in acute B-cell lymphoblastic leukemia in children is noted in the work of Rosales-Rodríguez et al. [25]. CNA risk classifiers have become effective tools for predicting disease recurrence. However, their clinical use has yet to be translated into routine practice.

Detecting CNA and mutations simultaneously during diagnosis and relapse is clinically important for predicting tumor clones’ evolution in B-ALL patients. New genomic strategies for detecting different genetic lesions are being addressed by developing specific panels for each type of hematologic malignancy aimed to facilitate risk stratification and improve customized treatment strategies for ALL [26].

A recent study proposes an additional stratification index for B-ALL patients based on changes in the DNA copy number variations identified by multiple ligation probe amplification (MLPA) [27]. Copy number alterations in the aforementioned study, as well
as in our study, were associated with poor prognosis and the lowest OS as well as EFS rates [27].

5. Conclusions

One can conclude that STR analysis is an effective, easy, and low-cost tool for detecting LOH in ALL patients, although it is limited by incomplete coverage by common STR panels. In contrast, CMA with single nucleotide polymorphism (SNP) probes has more extensive coverage and has proven its effectiveness in identifying both copy number alterations and copy neutral LOH [28–32]. Thus, CMA can provide clinically significant information that complements cytogenetic analysis. At the same time, translation of CMA into routine clinical testing is hampered by its comparatively complicated use and high costs. Here, STR in our view represents a viable alternative. We therefore in conclusion propose applying CMA to study LOH and thereby identify the whole picture of clinically relevant loci. Based thereon, extended STR panels can be developed to be readily translated into routine use in ALL diagnostics.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/genes13030398/s1, Table S1: Distribution of LOH by loci in B-ALL LOH-positive patients, Table S2: Distribution of LOH by loci in T-ALL LOH-positive patients, Table S3: Distribution of LOH by loci in MPAL LOH-positive patients, Table S4: CMA results for patients with aberrant STR loci in tumor DNA.

Author Contributions: Conceptualization, N.R., O.G. and A.S.; methodology, N.R.; formal analysis, J.C., E.K. and S.K.; investigation, Y.K., A.Y., T.O.; resources, O.G., G.I., K.Z., H.J., E.P.; writing—original draft preparation, N.R. and Y.K.; writing—review and editing, A.S.; supervision, A.S. and E.P.; funding acquisition, N.R. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by The Foundation for Cancer Research Support (Russia) RakFond: 5.2019.

Institutional Review Board Statement: The study was approved by the Ethics Committee of the National Research Center for Hematology (protocol #157/2 September 2021) and conducted in accordance with the Declaration of Helsinki of 1975, as revised in 2008.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Malard, F.; Mohty, M. Acute lymphoblastic leukaemia. Lancet 2020, 395, 1146–1162. [CrossRef]
2. Mrózek, K.; Harper, D.P.; Aplan, P.D. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol./Oncol. Clin. N. Am. 2009, 23, 991–1010. [CrossRef] [PubMed]
3. Piskunova, I.S.; Obukhova, T.N.; Parovichnikova, E.N.; Kulikov, S.M.; Troitskaya, V.V.; Gavrilina, O.A.; Savchenko, V.G. Structure and significance of cytogenetic abnormalities in adult patients with Ph-negative acute lymphoblastic leukemia. Ter. Arkhiv 2018, 90, 30–37. [CrossRef] [PubMed]
4. Thiagalingam, S.; Foy, R.L.; Cheng, K.; Lee, H.J.; Thiagalingam, A.; Ponte, J.F. Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: Molecular basis of its occurrence. Curr. Opin. Oncol. 2002, 14, 65–72. [CrossRef]
5. Makishima, H.; Maciejewski, J.P. Pathogenesis and consequences of uniparental disomy in cancer. Clin. Cancer Res. 2011, 17, 3913–3923. [CrossRef]
6. Carroll, A.J.; Shago, M.; Mikhail, F.M.; Raimondi, S.C.; Hirsch, B.A.; Loh, M.L.; Raetz, E.A.; Borowitz, M.J.; Wood, B.L.; Maloney, K.W.; et al. Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children’s Oncology Group. Cancer Genet. 2019, 238, 62–68. [CrossRef]
7. Bhargava, A.; Fuentes, F.F. Mutational dynamics of microsatellites. Mol. Biotechnol. 2010, 44, 250–266. [CrossRef]
8. Takeuchi, S.; Tsukasaki, K.; Bartram, C.R.; Seriu, T.; Zimmermann, M.; Schrappe, M.; Park, S.; Taguchi, H.; Koeffler, H.P.; Takeuchi, N. Long-term study of the clinical significance of loss of heterozygosity in childhood acute lymphoblastic leukemia. Leukemia 2003, 17, 149–154. [CrossRef]
9. Chambon-Pautas, C.; Cavé, H.; Gérard, B.; Guidal-Giroux, C.; Duval, M.; Vilmer, E.; Grandchamp, B. High-resolution allelotype analysis of childhood B-lineage acute lymphoblastic leukemia. Leukemia 1998, 12, 1107–1113. [CrossRef]
10. Baccichet, A.; Qualman, S.K.; Sinnett, D. Allelic loss in childhood acute lymphoblastic leukemia. Leuk. Res. 1997, 21, 817–823. [CrossRef]

11. Merup, M.; Moreno, T.C.; Heyman, M.; Rönnberg, K.; Grandér, D.; Detlofsson, R.; Rasool, O.; Liu, Y.; Söderhäll, S.; Julisson, G.; et al. 6q deletions in acute lymphoblastic leukemia and non-Hodgkin’s lymphomas. Blood 1998, 91, 3397–3400. [CrossRef][PubMed]

12. Cavé, H.; Avet-Loiseau, H.; Devaux, I.; Rondeau, G.; Boutard, P.; Lebrun, E.; Méchinaud, F.; Vilmer, E.; Grandchamp, B. Deletion of chromosomal region 13q14.3 in childhood acute lymphoblastic leukemia. Leukemia 2001, 15, 371–376. [CrossRef][PubMed]

13. Patel, H.S.; Kantarjian, H.M.; Bueso-Ramos, C.E.; Medeiros, L.J.; Haidar, M.A. Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia. Genes Chromosomes Cancer 2005, 42, 87–94. [CrossRef]

14. Chung, C.Y.; Kantarjian, H.; Haidar, M.; Starostik, P.; Manshouri, T.; Gidel, C.; Freireich, E.; Keating, M.; Albright, M. Deletions in the 13q14 locus in adult lymphoblastic leukemia: Rate of incidence and relevance. Cancer 2000, 88, 1359–1364. [CrossRef]

15. Walters, R.; Kantarjian, H.M.; Keating, M.J.; Estey, E.H.; Trujillo, J.; Cork, A.; McCredie, K.B.; Freireich, E.J. The importance of cytogenetic studies in adult acute lymphocytic leukemia. Am. J. Med. 1990, 89, 579–587. [CrossRef]

16. Faderl, S.; Gidel, C.; Kantarjian, H.M.; Manshouri, T.; Keating, M.; Albright, M. Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia. Leuk. Res. 2001, 25, 39–43. [CrossRef]

17. Haidar, M.A.; Kantarjian, H.; Manshouri, T.; Chang, C.-Y.; O’Brien, S.; Freireich, E.; Keating, M.; Albright, M. ATM gene deletion in patients with adult acute lymphoblastic leukemia. Cancer 2000, 88, 1057–1062. [CrossRef]

18. Kanerva, J.; Niini, T.; Vettenranta, K.; Rönnberg, K.; Grandchamp, B. Deletion of chromosome 13q in adult precursor B-cell acute lymphoblastic leukemia. Haematologica 1998, 83, 371–376. [CrossRef][PubMed]

19. Chen, C.; Heng, E.Y.H.; Lim, A.S.T.; Lau, L.C.; Lim, T.H.; Wong, G.C.; Tien, S.L. Chromosomal microarray analysis is superior in detecting cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay. J. Mol. Diagn. JMD 2016, 18, 595–603. [CrossRef][PubMed]

20. Baughn, L.B.; Biegel, J.A.; South, S.T.; Smolarek, T.A.; Volkert, S.; Carroll, A.J.; Heerema, N.A.; Zweidler-McKay, P.A.; Loh, M.; et al. Integration of cytogenomic data for furthering the characterization of Pediatric B-cell acute lymphoblastic leukemia: A multi-institution, multi-platform microarray study. Cancer Genet. 2015, 208, 1–18. [CrossRef]

21. Forero-Castro, M.; Robledo, C.; Benito, R.; Aíbáigar, M.; Martin, A.; Arefi, M.; Fuster, J.L.; Heras, N.D.L.; Rodriguez, J.N.; Quintero, J.; et al. Genome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome. PLoS ONE 2016, 11, e0148972. [CrossRef][PubMed]

22. Takeuchi, S.; Koike, M.; Seriu, T.; Bartram, C.; Slater, J.; Park, S.; Miyoshi, I.; Koefler, H. Homozygous deletions at 9p21 in childhood acute lymphoblastic leukemia detected by microsatellite analysis. Leukemia 1997, 11, 1636–1640. [CrossRef]

23. Heerema, N.A.; Sather, H.N.; Sensel, M.G.; Liu-Mares, W.; Lange, B.J.; Bostrom, B.C.; Nachman, J.B.; Steinherz, P.G.; Hutchinson, R.; Gaynon, P.S.; et al. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children’s Cancer Group. Blood 1999, 94, 1537–1544.

24. Nahi, H.; Hägglund, H.; Ahlgren, T.; Bernell, P.; Hardling, M.; Karlsson, K.; Lazarevic, V.L.; Linderholm, M.; Smedmyr, B.; Åström, M.; et al. An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: A multi-center study. J. Mol. Diagn. JMD 2016, 18, 595–603. [CrossRef][PubMed]

25. Nahi, H.; Avet-Loiseau, H.; Devaux, I.; Rondeau, G.; Boutard, P.; Lebrun, E.; Masure, F.; Vilmer, E.; Grandchamp, B. Deletion of chromosomal region 13q14.3 in childhood acute lymphoblastic leukemia. J. Mol. Diagn. JMD 2016, 18, 595–603. [CrossRef][PubMed]

26. Faderl, S.; Gidel, C.; Kantarjian, H.M.; Manshouri, T.; Keating, M.; Albright, M. Loss of heterozygosity but scarcity of microsatellite instability at chromosomal breakpoint cluster regions in adult leukemias. Blood 1996, 88, 1026–1034. [CrossRef]

27. Irving, J.A.E.; Bloodworth, L.; Bown, N.P.; Case, M.C.; Hogarth, L.A.; Hall, A.G. Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis. Cancer Res. 2005, 65, 3035–3038. [CrossRef]

28. Petersson, J.F.; Aggarwal, N.; Smith, C.A.; Gollin, S.; Surti, U.; Rajkovic, A.; Sverdlov, S.H.; Yatsenko, S.A. Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? Oncotarget 2015, 6, 18845–18862. [CrossRef]

29. Chen, C.; Heng, E.Y.H.; Lim, A.S.T.; Lau, L.C.; Lim, T.H.; Wong, G.C.; Tien, S.L. Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay. Int. J. Lab. Hematol. 2019, 41, 561–571. [CrossRef]

30. Wang, Y.; Miller, S.; Roulston, D.; Bixby, D.; Shao, L. Genome-Wide Single-Nucleotide Polymorphism Array Analysis Improves Prognostication of Acute Lymphoblastic Leukemia/Lymphoma. J. Mol. Diagn. JMD 2016, 18, 595–603. [CrossRef][PubMed]

31. Peterson, J.F.; Van Dyke, D.L.; Hoppman, N.L.; Kearney, H.M.; Sukow, W.R.; Greipp, P.T.; Ketterling, R.P.; Baughn, L.B. The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms: An ACLPS Critical Review. Am. J. Clin. Pathol. 2018, 150, 375–384. [CrossRef][PubMed]